DexCom, Inc. (NASDAQ:DXCM) CFO Sells $270,288.00 in Stock

DexCom, Inc. (NASDAQ:DXCMGet Rating) CFO Jereme M. Sylvain sold 2,400 shares of the firm’s stock in a transaction dated Monday, November 21st. The shares were sold at an average price of $112.62, for a total value of $270,288.00. Following the transaction, the chief financial officer now directly owns 67,237 shares of the company’s stock, valued at approximately $7,572,230.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

DexCom Stock Up 1.7 %

DXCM opened at $112.92 on Friday. DexCom, Inc. has a fifty-two week low of $66.89 and a fifty-two week high of $152.62. The business has a 50-day moving average of $101.41 and a 200-day moving average of $87.91. The company has a debt-to-equity ratio of 1.08, a current ratio of 3.77 and a quick ratio of 3.43. The company has a market capitalization of $43.62 billion, a PE ratio of 208.15, a price-to-earnings-growth ratio of 4.26 and a beta of 1.21.

Institutional Investors Weigh In On DexCom

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its stake in shares of DexCom by 1.2% during the 3rd quarter. Vanguard Group Inc. now owns 43,682,426 shares of the medical device company’s stock worth $3,518,183,000 after purchasing an additional 511,557 shares in the last quarter. Baillie Gifford & Co. raised its stake in shares of DexCom by 297.4% during the 2nd quarter. Baillie Gifford & Co. now owns 18,099,399 shares of the medical device company’s stock worth $1,348,948,000 after purchasing an additional 13,545,106 shares in the last quarter. Sands Capital Management LLC raised its stake in shares of DexCom by 327.3% during the 2nd quarter. Sands Capital Management LLC now owns 17,902,213 shares of the medical device company’s stock worth $1,334,252,000 after purchasing an additional 13,712,968 shares in the last quarter. Jennison Associates LLC raised its stake in shares of DexCom by 229.3% during the 2nd quarter. Jennison Associates LLC now owns 8,563,611 shares of the medical device company’s stock worth $638,246,000 after purchasing an additional 5,963,328 shares in the last quarter. Finally, Clearbridge Investments LLC raised its stake in shares of DexCom by 333.0% during the 2nd quarter. Clearbridge Investments LLC now owns 5,707,510 shares of the medical device company’s stock worth $425,381,000 after purchasing an additional 4,389,431 shares in the last quarter. 92.34% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages recently weighed in on DXCM. Jefferies Financial Group began coverage on DexCom in a research note on Wednesday, October 12th. They set a “buy” rating and a $125.00 target price for the company. Stifel Nicolaus upped their target price on DexCom from $112.00 to $120.00 and gave the company a “buy” rating in a report on Friday, October 7th. StockNews.com began coverage on DexCom in a report on Wednesday, October 12th. They set a “hold” rating for the company. Morgan Stanley upped their target price on DexCom from $107.00 to $117.00 and gave the company an “equal weight” rating in a report on Friday, October 28th. Finally, Cowen upped their target price on DexCom from $85.00 to $114.00 in a report on Friday, October 28th. Three equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat.com, DexCom has a consensus rating of “Moderate Buy” and an average price target of $120.24.

About DexCom

(Get Rating)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.

Further Reading

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.